MIEN1-derived peptides

MIEN1-derived peptides (specifically LA3IK and RP-7) are first-in-class anticancer peptides derived from the conserved immunoreceptor tyrosine-based activation motif (ITAM) and prenylation motif sequences of the Migration and Invasion Enhancer 1 (MIEN1) protein, a cancer-specific oncogene overexpressed in multiple aggressive cancers including breast and prostate cancer. These therapeutic peptides act as dominant-negative inhibitors of the MIEN1 signaling pathway, disrupting cancer cell migration, invasion, and epithelial-to-mesenchymal transition (EMT). LA3IK, a hexamer peptide, has also been shown to selectively disrupt EGFR–ERBB2 heterodimerization, reducing downstream NF-κB, Src, and STAT3 signaling. D-isomer analogs (such as D-LA3IK and D-RP-7) have been developed to improve metabolic stability and bioavailability. The compounds are in preclinical development by researchers at the University of North Texas Health Science Center.

Other names

MIEN1 therapeutic peptidesMIEN-1 therapeutic peptidesMIEN 1 therapeutic peptides